National Taiwan University Hospital
Taipei, Taiwan
Location status: Recruiting
Location contact
Chih-Yang Chan, MD Phd
CONTACT
NCT Number: NCT06364449
Our study aim was to utilize a decision tree analysis (DTA) model to gain insight into the decision-making process within a multiple-center cohort.
Interested in participating?
Request Info18 year–100 year
All sexes
Observational
Taipei, Taiwan
Location status: Recruiting
Chih-Yang Chan, MD Phd
CONTACT
Scientific research focuses on limited parameters, aims to confirm hypotheses, and has minor uncertainties. In contrast, medical decisions involve many unknowns. Physicians must use all available knowledge to make the best decisions. However, decision-making can become unpredictable when limited evidence exists, leading to non-reproducible outcomes.
According to clinical guidelines, patients who need pre-kidney replacement therapy (pre-KRT) and opt for hemodialysis (HD) with a reasonable life expectancy should have arteriovenous (AV) access created. Nevertheless, constructing an AVF has limitations. [Additionally, the maturation rate of AVF is suboptimal. Therefore, after careful consideration of the patient's end-stage kidney disease (ESKD) life plan, the suggested order of AV access types and locations starts a native distal forearm radiocephalic AVF, followed by a native proximal forearm AVF, a forearm arteriovenous graft (AVG), then an upper arm AVG creation.[Lok et al., 2020] However, the decision-making process for selecting hemodialysis access is shared between patients, physicians, and the surgeon's discretion.
Therefore, clinical kidney practice requires effective decision-making to address ESKD life plan and AV access concerns while minimizing harm. Decision analysis models can bridge the gap between research and decision-making. Our study aim was to utilize a decision tree analysis (DTA) model to gain insight into the decision-making process within a multiple-center cohort.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention
Time frame: postoperativ 3 -12 months
identifying parameters that predicted AV access choices among the four types
Time frame: postoperativ 3 -12 months
The secondary objective was to determine factors affecting clinical use of the targeted AV access over a variable timeframe
Contact information is provided by the study sponsor or research team.
National Taiwan University Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07153939
Arteriovenous Fistula, Arteriovenous Malformations
Dothan, Alabama, United States
View Trial DetailsNCT05654103
Arteriovenous Fistula, Arteriovenous Malformations
Los Angeles, California, United States
View Trial DetailsNCT06807099
Arteriovenous Fistula, Arteriovenous Malformations
Dothan, Alabama, United States
View Trial DetailsNCT07559942
Arteriovenous Fistula, Arteriovenous Fistula Occlusion
Lahore, Punjab Province, Pakistan
View Trial Details